You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 51 - 60 of 3279 results
  1. Development of brain-penetrant COMT inhibitors for the treatment of depressive disorders

    SBC: PSY THERAPEUTICS, INC.            Topic: 101

    PROJECT SUMMARYMajor depressive disorder (MDD) is a serious, debilitating, and often recurring disorder with a substantial lifetime risk and a high societal cost. Depressed patients frequently display a variety of co-morbid symptoms, including depressed moods, loss of motivation and/or reductions in the ability to experience pleasure (anhedonia), loss of interest and energy, combined with psycholo ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Highly Specific and Sensitive HSV-1 and HSV-2 Diagnostic Test

    SBC: Rational Vaccines, Inc.            Topic: NIAID

    Project Summary: Infections with Herpes Simplex Virus type-1 (HSV-1) or Herpes Simplex Virus type-2 (HSV- 2), the causative agents of genital herpes, are highly prevalent worldwide. The World Health Organization (WHO) estimates that more than 3.7 billion people under the age of 50 are infected with HSV-1, and approximately 490 million are infected with HSV-2 worldwide. Despite being preventable, H ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A novel system and procedure for non-surgical placement of EEG electrodes in mice

    SBC: NEUROTARGETING SYSTEMS            Topic: 101

    Abstract The development of new efficient tools for measuring electroencephalogram (EEG) in freely moving mice is highly important in both academic and commercial research studies. EEG provides valuable information on the impact of drugs on arousal and sleep architecture, and allows for the assessment of their neuropharmacological characteristics in vivo, including central exposure and information ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A simulation platform to predict dose and therapeutic window of immunocytokines

    SBC: Applied BioMath, LLC            Topic: NIAID

    Project Summary/Abstract Immunocytokines (ICs) are fusion proteins of an engineered cytokine conjugated to an antibody. These novel molecules are the next generation of cytokine-based immunotherapies with potential applications in a diverse range of diseases such as rheumatoid arthritis (RA), psoriasis, and cancer. ICs are designed to selectively target diseased tissue or specific immune cells wit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Untethered high channel count electrophysiology for freely-moving animals

    SBC: Leaflabs, LLC            Topic: 101

    PROJECT SUMMARY Recording whole-brain activity with single neuron resolution and millisecond timescale precision is crucial to understanding how individual cells and complex neural circuits interact in both time and space. Simultaneous recording and stimulation of large populations of neurons distributed throughout the brain are needed to rigorously evaluate theories of neural computation at the c ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Enabling Subcutaneous Delivery of Therapeutic Monoclonal Antibodies via Hydrogel Microparticles

    SBC: ACOUSTICABIO, INC.            Topic: 100

    ABSTRACT Monoclonal antibodies (mAbs) provide unchallenged specificity compared to small molecules, representing a growing market of 150+ billion dollars. Due to their structural complexity and poor stability, however, they remain difficult to formulate at high concentrations, making intravenous (IV) delivery of mAbs the “gold standard”. IV injections present major drawbacks, such as patient d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Population monitoring of stress markers in underserved communities

    SBC: GINER INC            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Daily stresses, as well as social, emotional, and financial challenges, can activate physiological stress. Current public health monitoring systems cannot quantify community stress levels for millions of low-resource and underserved communities. By identifying communities experiencing high levels of stress using wastewater- based epidemiology, public health professionals c ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Multi-Modal Wearable Sensor for Early Detection of Cognitive Decline and Remote Monitoring of Cognitive-Motor Decline Over Time

    SBC: BIOSENSICS LLC            Topic: NIA

    ABSTRACT Recent demographic changes have led to the emergence of the so-called “dementia epidemic”. Dementia causes great stress to medical, social, and informal care and is currently affecting approximately 55 million persons worldwide. This number is projected to increase to 75.6 million by 2030 and 135.5 million by 2050. Alzheimer’s disease (AD) is a degenerative brain disease and the mos ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy

    SBC: ABBRATECH INC.            Topic: 300

    ABSTRACT Current therapeutic antibodies target the cell surface and within the external cellular environment. Yet intracellular proteins make up half of the proteome. Having a facile means of targeting those intracellular proteins for the generation of therapeutic antibodies would be highly desirable. Targeting MHC complexed with neoantigens from intracellular proteins would greatly allow the gene ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government